News

The company’s wrinkles or nasolabial folds Phase III trials were conducted under an FDA special protocol assessment. Isolagen currently estimates that its unrestricted, available cash resources will allow

DiaMedica said that Dr Waters is an experienced scientist and pharmaceutical industry executive with more than 24 years of active leadership and involvement in drug development. Dr Waters’s

The company reported a net loss of $38.1 million, or $0.49 per share, for the full year 2008, compared to a net loss of $33.9 million, or $0.47

Net loss for the year 2008 was $8.42 million, or $0.71 per share, compared to a net loss of $8.94 million, or $0.80 per share, for 2007. The

Isolagen, an aesthetic and therapeutic company, has announced positive top-line efficacy results from a Phase II/III clinical study of the Isolagen Therapy for the treatment of moderate to

MiddleBrook Pharmaceuticals, a developer and marketer of anti-infective products, has reported net loss of $11.6m for the fourth quarter of 2008, compared to a net loss of $9.1m

Initiate Systems, a provider of master data management solutions, has announced that UMass Memorial Health Care of Worcester, Massachusetts, has selected its Initiate Interoperable Health software to provide

Power Medical Interventions, a manufacturer and marketer of intelligent surgical instruments, has reported a net loss applicable to common shares of $9.4m, or $0.55 per basic and diluted

China Sky One Medical has obtained production approval from the State Food and Drug Administration in China for calcium folinate injection. The company said that another two new